Corticosteroids in the treatment of acute exacerbations of chronic obstructive pulmonary disease

International Journal of COPD

Volumn 9, Issue , 2014, Pages 421-430

  Woods, J Andrew ^a   Wheeler, James S ^a   Finch, Christopher K ^b   Pinner, Nathan A ^c  

^a WINGATE UNIVERSITY   (United States)

^b METHODIST UNIVERSITY HOSPITAL   (United States)

^c AUBURN UNIVERSITY   (United States)

Author keywords

Chronic obstructive pulmonary disease; Exacerbation

Indexed keywords

CORTICOSTEROID; GLUCOCORTICOID; METHYLPREDNISOLONE; PLACEBO; PREDNISOLONE; PREDNISONE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; DRUG USE; HOSPITALIZATION; HUMAN; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY AIRFLOW; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME;

CHRONIC OBSTRUCTIVE PULMONARY DISEASE; EXACERBATION;

ADRENAL CORTEX HORMONES; DISEASE PROGRESSION; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; HUMANS; LUNG; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECOVERY OF FUNCTION; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84899863508     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S51012     Document Type: Review

References (44)

1. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. Eur Respir J. 2006;28:523-532.
2. National Heart, Lung, and Blood Institute. Morbidity and Mortality: Chart Book on Cardiovascular, Lung, and Blood Diseases. Bethesda (MD): US Department of Health and Human Services, Public Health Service, National Institutes of Health; 2012. Available from: http://www.nhlbi.nih.gov/resources/docs/cht-book.htm. Accessed March 17, 2014.
3. Mathers C, Boerma T, Fat DM. The Global Burden of Disease: 2004 Update. Geneva: World Health Organization; 2008.
4. Murphy SL, Xu JQ, Kochanek KD. Death: preliminary data for 2008. Natl Vital Stat Rep. 2012;60:1-51.
5. Global initiative for chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Bethesda (MD); 2013. Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2013_Feb20.pdf. Accessed March 17, 2014.
6. Guarascio AJ, Ray SM, Finch CK, Self TH. The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clinicoecon Outcomes Res. 2013;5:235-245.
7. American Thoracic Society/European Respiratory Society. Standards for the Diagnosis and Management of Patients with COPD. Version 1.2. New York: American Thoracic Society; 2004 (updated 2005). Available from: http://www.thoracic.org/go/copd. Accessed March 17, 2014.
8. O'Reilly JF, Williams AE, Holt K, Rice L. Defining COPD exacerbations: impact on estimation of incidence and burden in primary care. Prim Care Respir J. 2006;15:346-353.
9. Johnston AK, Mannino DM. Epidemiology of COPD exacerbations. In: Wedzicha JA, Martinez FJ, editors. Exacerbations of Chronic Obstructive Pulmonary Disease. London: Informa Healthcare; 2008:15-26.
10. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57:847-852.
11. Suissa S, Dell'aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012;67:957-963.
12. National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease: Management of chronic obstructive pulmonary disease in adults in primary and secondary care (partial update). 2010. Available from: http://guidance.nice.org.uk/cg101. Accessed March 17, 2014.
13. Lindenauer PK, Pekow PS, Lahti MC, Lee Y, Benjamin EM, Rothberg MB. Association of corticosteroid dose and route of administration with risk of treatment failure in acute exacerbation of chronic obstructive pulmonary disease. JAMA. 2010;303:2359-2367.
14. O'Donnell DE, Hernandez P, Kaplan A, etal. Canadian thoracic society recommendations for management of chronic obstructive pulmonary disease-2008 update-highlights for primary care. Can Respir J. 2008;15 Suppl A:1A-8A.
15. Evensen A. Management of COPD exacerbations. Am Fam Physician. 2010;81:607-613.
16. Davies L, Angus RM, Calverley PM. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet. 1999;354:456-460.
17. Thompson WH, Nielson CP, Calvalho P, Charan NB, Crowley JJ. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med. 1996;154:407-412.
18. Al-Habert S, Rogers HJ. Pharmacokinetics of intravenous and oral prednisolone. Br J Clin Pharmacol. 1980;10:503-508.
19. Beeral F, Jick H, Tyler JM. A controlled study of the effect of prednisone on air-flow obstruction in severe pulmonary emphysema. N Engl J Med. 1963;268:226-230.
20. Clifton M, Stuart-Harris CH. Steroid therapy in chronic bronchitis. Lancet. 1962;1:1311-1313.
21. Franklin W, Michelson AL, Lowell FC, Schiller IW. Bronchodilators and corticosteroids in the treatment of obstructive pulmonary emphysema. N Engl J Med. 1958;258:774-778.
22. Kiein RC, Salbaggio JE, Kundur VG. The response of patients with "idiopathic" obstructive pulmonary disease and "allergic" obstructive bronchitis to prednisone. Ann Intern Med. 1969;71:711-718.
23. Morgan WK, Rusche E. A controlled trial of the effect of steroids in obstructive airway disease. Ann Intern Med. 1964;61:248-254.
24. Moyes EN, Kershaw RA. Long-continued treatment with tetracycline and prednisolone in chronic bronchitis: a controlled trial. Lancet. 1957;2:1187-1191.
25. Petty TL, Brink GA, Miller MW, Corsello PR. Objective functional improvement in chronic airway obstruction. Chest. 1970;57: 216-223.
26. Albert RK, Martin TR, Lewis SW. Controlled clinical trial of methylprednisolone in patients with chronic bronchitis and acute respiratory insufficiency. Ann Intern Med. 1980;92:753-758.
27. Emerman CL, Connors AF, Lukens TW, May ME, Effron D. A randomized controlled trial of methylprednisolone in the emergency treatment of acute exacerbations of COPD. Chest. 1989;95:563-567.
28. Bullard MJ, Liaw SJ, Tsai YH, Min HP. Early corticosteroid use in acute exacerbation of chronic airflow limitation. Am J Emerg Med. 1996;14:139-143.
29. Murata GH, Gorby MS, Chick TW, Halperin AK. Intravenous and oral corticosteroids for the prevention of relapse after treatment of decompensated COPD: effect on patients with a history of multiple relapses. Chest. 1990;98:845-849.
30. Niewoehner DE, Erbland ML, Deupree RH, etal. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med. 1999;340;1941-1947.
31. Aaron SD, Vandemheen KL, Hevert P, etal. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med. 2003;348:2618-2625.
32. Walters JA, Gibson PG, Wood-Baker R, Hannary M, Walters EH. Systemic corticosteroids for acute exacerbation of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2009;(1):CD001288.
33. Sayiner A, Aytemur ZA, Cirit M, Unsal I. Systemic glucocorticoids in severe exacerbations of COPD. Chest. 2001;119:726-730.
34. Walters JA, Want W, Morley C, Soltani A, Wood-Baker R. Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2011;(10):CD006897.
35. Leuppi JD, Schuetz P, Bingisser R, etal. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA. 2013;309:2223-2231.
36. Czock D, Keller F, Rasche FM, Häussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005;44:61-98.
37. Harrison BD, Stokes TC, Hart GJ, Vaughan DA, Ali NJ, Robinson AA. Need for intravenous hydrocortisone in addition to oral prednisolone in patients admitted to hospital with severe asthma without ventilator failure. Lancet. 1986;1:181-184.
38. Jónsson S, Kjartansson G, Gislaon D, Helgason H. Comparison of the oral and intravenous routes for treating asthma with methylprednisolone and theophylline. Chest. 1998;94:723-726.
39. Ratto D, Alfaro C, Sipsey J, Glovsky MM, Sharma OP. Are intravenous corticosteroids required in status asthmaticus? JAMA. 1988;260:527-529.
40. de Jong YP, Uil SM, Grotjohan HP, Postma DS, Kerstjens HA, van den Berg JW. Oral or IV prednisolone in the treatment of COPD exacerbations: a randomized, controlled, double-blind study. Chest. 2007;132:1741-1747.
41. Gunen H, Hacievliyagil SS, Yetkin O, Gulbas G, Mutlu LC, In E. The role of nebulised budesonide in the treatment of exacerbations of COPD. Eur Respir J. 2007;29:660-667.
42. Johansson SA, Andersson KE, Brattsand R, Gruvstad E, Hedner P. Topical and systemic glucocorticoid potencies of budesonide, beclomethasone dipropionate and prednisolone in man. Eur J Respir Dis Suppl. 1982;122:74-82.
43. Brogden RN, McTavish D. Budesonide: an updated review of its pharmacological properties and therapeutic efficacy in asthma and rhinitis. Drugs. 1992;44:375-407.
44. Maltais F, Ostinelli J, Borbeau J, etal. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease; a randomized controlled trial. Am J Respir Crit Care Med. 2002;165:698-703.